TY - JOUR
T1 - Risk and survival of patients with medullary thyroid cancer
T2 - National perspective
AU - Al-Qurayshi, Zaid
AU - Khadra, Helmi
AU - Chang, Kristi
AU - Pagedar, Nitin
AU - Randolph, Gregory W.
AU - Kandil, Emad
N1 - Publisher Copyright:
© 2018 Elsevier Ltd
PY - 2018/8
Y1 - 2018/8
N2 - Background: Medullary thyroid carcinoma (MTC) is a neuroendocrine tumor account for 1–2% of thyroid cancer. In this study, we aim to examine the characteristics and survival of patients with MTC. Methods: A retrospective cohort study utilizing the National Cancer Data Base, 2004–2014. The study population included adults with either MTC (cases) or with differentiated thyroid cancer (DTC) (controls). Results: A total of 2,776 MTC and 171,631 DTC patients were included. The median follow-up time for MTC was 55.5 months (interquartile range: 31.2–84.6 months). As compared to DTC, patients with MTC were more likely to be ≥ 45-year old, male, and Black (p < 0.001). Neck dissection improved survival in patients with stage III [HR: 0.26, 95%CI: (0.10, 0.64), p = 0.004]. In patients with stages I and II, neck dissections did not add significant survival benefit to thyroidectomy [stage I, HR: 1.00, 95%CI: (0.54, 1.86), p = 0.99],[stage 2, HR: 0.72, 95%CI: (0.40, 1.29), p = 0.27]. However, neck dissections upgraded staging to N1A and N1B in 17.7% and 14.3% of patients with clinically N0 neck, respectively. In stage IV, thyroidectomy with neck dissection had the highest 5-year survival (84.9%), but this was not significantly different from thyroidectomy alone (84.1%); Patients who had thyroidectomy and EBRT with or without neck dissection had a lower survival than thyroidectomy alone (p < 0.01). Conclusions: Neck dissection performed on patients with clinically N0 neck, is important for accurate staging and associate with improved survival in advanced stages. Thyroidectomy and neck dissection in stage IV not only have palliative role but also add survival advantage.
AB - Background: Medullary thyroid carcinoma (MTC) is a neuroendocrine tumor account for 1–2% of thyroid cancer. In this study, we aim to examine the characteristics and survival of patients with MTC. Methods: A retrospective cohort study utilizing the National Cancer Data Base, 2004–2014. The study population included adults with either MTC (cases) or with differentiated thyroid cancer (DTC) (controls). Results: A total of 2,776 MTC and 171,631 DTC patients were included. The median follow-up time for MTC was 55.5 months (interquartile range: 31.2–84.6 months). As compared to DTC, patients with MTC were more likely to be ≥ 45-year old, male, and Black (p < 0.001). Neck dissection improved survival in patients with stage III [HR: 0.26, 95%CI: (0.10, 0.64), p = 0.004]. In patients with stages I and II, neck dissections did not add significant survival benefit to thyroidectomy [stage I, HR: 1.00, 95%CI: (0.54, 1.86), p = 0.99],[stage 2, HR: 0.72, 95%CI: (0.40, 1.29), p = 0.27]. However, neck dissections upgraded staging to N1A and N1B in 17.7% and 14.3% of patients with clinically N0 neck, respectively. In stage IV, thyroidectomy with neck dissection had the highest 5-year survival (84.9%), but this was not significantly different from thyroidectomy alone (84.1%); Patients who had thyroidectomy and EBRT with or without neck dissection had a lower survival than thyroidectomy alone (p < 0.01). Conclusions: Neck dissection performed on patients with clinically N0 neck, is important for accurate staging and associate with improved survival in advanced stages. Thyroidectomy and neck dissection in stage IV not only have palliative role but also add survival advantage.
KW - Hospital volume
KW - Medullary thyroid carcinoma
KW - Neck dissection
KW - Overall survival
KW - Radiotherapy
KW - Surgery
KW - Thyroidectomy
UR - http://www.scopus.com/inward/record.url?scp=85048259310&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85048259310&partnerID=8YFLogxK
U2 - 10.1016/j.oraloncology.2018.06.002
DO - 10.1016/j.oraloncology.2018.06.002
M3 - Article
C2 - 30098780
AN - SCOPUS:85048259310
SN - 1368-8375
VL - 83
SP - 59
EP - 63
JO - Oral Oncology
JF - Oral Oncology
ER -